SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-22-027751
Filing Date
2022-11-18
Accepted
2022-11-18 16:40:59
Documents
15
Period of Report
2022-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20221117_8k.htm   iXBRL 8-K 28944
2 EXHIBIT 99.1 ex_448804.htm EX-99.1 23106
7 logo02.gif GRAPHIC 4839
  Complete submission text file 0001437749-22-027751.txt   202466

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dffn-20221114.xsd EX-101.SCH 3602
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20221114_def.xml EX-101.DEF 11920
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20221114_lab.xml EX-101.LAB 15967
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20221114_pre.xml EX-101.PRE 12131
9 EXTRACTED XBRL INSTANCE DOCUMENT dffn20221117_8k_htm.xml XML 2665
Mailing Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902
Business Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 221402467
SIC: 2834 Pharmaceutical Preparations